Contacts
Superior Investor Relations:
(248) 234-7104
Investor.Relations@supind.com
Superior Industries International, Inc. (“Superior” or the “Company”) (NYSE:SUP) announced today that it will release financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.
A conference call will be held to discuss the financial results on Thursday, November 3, 2022 at 9:00 AM ET and will be hosted by Majdi Abulaban, President and Chief Executive Officer, Tim Trenary, Executive Vice President and Chief Financial Officer, and Joanne Finnorn, Senior Vice President, Investor Relations, Sustainability and Corporate Secretary.
The conference call may be accessed by dialing +1 786-697-3501 for participants in the U.S./Canada or 866-580-3963 for participants outside the U.S./Canada using the required conference ID 1470142. The live conference call can also be accessed by logging into the Company’s website at www.supind.com or by clicking this link: earnings call webcast. A replay of the webcast will be available on the Company’s website immediately following the conclusion of the call.
About Superior Industries
Superior is one of the world’s leading aluminum wheel suppliers. Superior’s team collaborates with customers to design, engineer, and manufacture a wide variety of innovative and high-quality products utilizing the latest light weighting and finishing technologies. Superior serves the European aftermarket with the brands ATS®, RIAL®, ALUTEC®, and ANZIO®. Headquartered in Southfield, Michigan, Superior is listed on the New York Stock Exchange. For more information, please visit www.supind.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221020005240/en/
Related news for (SUP)
- Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
- Superior Industries International, Inc. Receives NYSE Continued Listing Standards Notice
- MoBot’s Stock Market Highlights – 04/11/25 07:00 PM
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
- supernus pharmaceuticals to host webcast to review open-label phase 2a study of spn-820 for the treatment of major depressive disorder